Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.

Current oncology reports - 1 Mar 2009

Cowey C Lance, Rathmell W Kimryn

Abstract excerpt

The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Renal Cell
Share to VHL gene

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Kidney Neoplasms

Share to Mutation

Share to Prognosis

Share to Vascular Endothelial Growth Factor A

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 19216840
DOI: 10.1007/s11912-009-0015-5
PMCID: PMC2873025

Genes

VHL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy.PMID 19216840Read ↗

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.Semantic proximity Read ↗

Prognostic and predictive biomarkers in renal cell carcinoma.Semantic proximity Read ↗

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.Semantic proximity Read ↗

Role of VHL gene mutation in human renal cell carcinoma.Semantic proximity Read ↗

Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review.Semantic proximity Read ↗

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.Semantic proximity Read ↗

The von Hippel-Lindau geneSemantic proximity Read ↗

State of the science: an update on renal cell carcinoma.Semantic proximity Read ↗

Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinomaSemantic proximity Read ↗

The Clinicopathological Significance of Epigenetic Silencing of VHL Promoter and Renal Cell Carcinoma: A Meta-AnalysisSemantic proximity Read ↗

VHLinactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatmentSemantic proximity Read ↗

Renal Cell Carcinoma in von Hippel–Lindau Disease—From Tumor Genetics to Novel Therapeutic StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.